WallStSmart

Standard Biotools Inc (LAB)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 41484% more annual revenue ($35.48B vs $85.33M). MDT leads profitability with a 13.0% profit margin vs -87.8%. MDT earns a higher WallStSmart Score of 56/100 (C).

LAB

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LAB.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LAB1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

LAB4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$379.85M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-13.1%2/10

ROE of -13.1% — below average capital efficiency

Revenue GrowthGrowth
-14.2%2/10

Revenue declined 14.2%

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : LAB

The strongest argument for LAB centers on Price/Book.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : LAB

The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

LAB profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

LAB carries more volatility with a beta of 1.37 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Standard Biotools Inc

HEALTHCARE · MEDICAL DEVICES · USA

Standard Biotools Inc. (LAB) is a leading biotechnology firm committed to advancing the capabilities of genomic analysis and biological research through innovative tools and technologies. The company specializes in high-performance products designed specifically for laboratories focused on genomics and proteomics, significantly improving research accuracy and efficiency. By leveraging proprietary platforms, Standard Biotools empowers scientists to accelerate their discoveries and enhance the quality of their work. With a strategic position within the dynamic biotechnology landscape, LAB is poised to meet the rising demand for sophisticated analytical solutions vital to the life sciences industry.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?